Ras Oncogene-Mediated Progressive Silencing of Extracellular Superoxide Dismutase in Tumorigenesis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Cammarota, Francesca ^a   De Vita, Gabriella ^b   Salvatore, Marco ^a   Laukkanen, Mikko O ^a  

^a IRCCS SDN   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; EXTRACELLULAR SUPEROXIDE DISMUTASE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; MESSENGER RNA; MICRORNA 21; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN CDC42; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; SUPEROXIDE DISMUTASE;

ADVANCED CANCER; ANAPLASTIC THYROID CANCER; ANIMAL CELL; ARTICLE; AUTOREGULATION; CANCER CELL CULTURE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MESSENGER RNA SYNTHESIS; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYROID CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; ENZYMOLOGY; EXTRACELLULAR FLUID; GENE SILENCING; GENETICS; METABOLISM; ONCOGENE RAS; SECRETION (PROCESS); THYROID GLAND; THYROID TUMOR;

ANIMALS; CARCINOGENESIS; CELL LINE; EXTRACELLULAR FLUID; GENE SILENCING; GENES, RAS; HUMANS; RATS; SUPEROXIDE DISMUTASE; THYROID GLAND; THYROID NEOPLASMS;

EID: 84945968291     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/780409     Document Type: Article

References (47)

1. P.-O. Sjoquist and S. L. Marklund, "Endothelium bound extracellular superoxide dismutase type C reduces damage in reperfused ischaemic rat hearts," Cardiovascular Research, vol. 26,no. 4, pp. 347-350, 1992.
2. M. O. Laukkanen, P. Leppanen, P. Turunen, T. Tuomisto, J. Naarala, and S. Yla-Herttuala, "EC-SOD gene therapy reduces paracetamol-induced liver damage in mice," Journal of Gene Medicine, vol. 3, no. 4, pp. 321-325, 2001.
3. M. O. Laukkanen, A. Kivelä, T. Rissanen et al., "Adenovirusmediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta," Circulation, vol. 106, no. 15, pp. 1999-2003, 2002.
4. K. Ozumi, H. Tasaki,H. Takatsu et al., "Extracellular superoxide dismutase overexpression reduces cuff-induced arterial neointimal formation," Atherosclerosis, vol. 181, no. 1, pp. 55-62, 2005.
5. E. D. van Deel, Z. Lu, X. Xu et al., "Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction," Free Radical Biology and Medicine, vol. 44, no. 7, pp. 1305-1313, 2008.
6. J. P. Laurila, L. E. Laatikainen, M. D. Castellone, and M. O. Laukkanen, "SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression," PLoS ONE, vol. 4, no. 6,Article ID e5786, 2009.
7. M. D. Castellone, A. Langella, S. Cantara et al., "Extracellular superoxide dismutase induces mouse embryonic fibroblast proliferative burst, growth arrest, immortalization, and consequent in vivo tumorigenesis," Antioxidants and Redox Signaling, vol. 21, no. 10, pp. 1460-1474, 2014.
8. M. O. Laukkanen, F. Cammarota, T. Esposito,M. Salvatore, and M. D. Castellone, "Extracellular superoxide dismutase regulates the expression of small gtpase regulatory proteins GEFs, GAPs, and GDI," PLoS ONE, vol. 10, no. 3, Article IDe0121441, 2015.
9. J. P. Laurila, M. D. Castellone, A. Curcio et al., "Extracellular superoxide dismutase is a growth regulatory mediator of tissue injury recovery," MolecularTherapy, vol. 17, no. 3, pp. 448-454, 2009.
10. H. L. Maecker, Z. Yun, H. T. Maecker, and A. J. Giaccia, "Epigenetic changes in tumor Fas levels determine mmune escape and response to therapy," Cancer Cell, vol. 2, no. 2, pp. 139-148, 2002.
11. J. Sung, J. Turner, S. McCarthy et al., "Oncogene regulation of tumor suppressor genes in tumorigenesis," Carcinogenesis, vol. 26, no. 2, pp. 487-494, 2005.
12. S. Cairns-Smith and P. Karran, "Epigenetic silencing of theDNA repair enzyme O6-methylguanine-DNA methyltransferase in Mex-human cells," Cancer Research, vol. 52, no. 19, pp. 5257-5263, 1992.
13. H. Takada, I. Imoto, H. Tsuda et al., "ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation," Oncogene, vol. 24, no. 54, pp. 8051-8060, 2005.
14. X. Qian,G. Li, H. K. Asmussen et al., "Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 21, pp. 9012-9017, 2007.
15. R. Holliday, "A new theory of carcinogenesis," British Journal of Cancer, vol. 40, no. 4, pp. 513-522, 1979.
16. J. Covault, M. Perry, and R. Chalkley, "Effects of histone hyperacetylation and hypoacetylation on RNA synthesis in HTC cells," The Journal of Biological Chemistry, vol. 257, no. 22, pp. 13433-13440, 1982.
17. C. Gazin, N. Wajapeyee, S. Gobeil, C.-M. Virbasius, and M. R. Green, "An elaborate pathway required for Ras-mediated epigenetic silencing," Nature, vol. 449, no. 7165, pp. 1073-1077, 2007.
18. O. A. Kent and J. T. Mendell, "A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes," Oncogene, vol. 25, no. 46, pp. 6188-6196, 2006.
19. G. De Vita, L. Bauer, V. M. Correa Da Costa et al., "Dosedependent inhibition of thyroid differentiation by RAS oncogenes," Molecular Endocrinology, vol. 19, no. 1, pp. 76-89, 2005.
20. M. O. Laukkanen, P. Lehtolainen, P. Turunen et al., "Rabbit extracellular superoxide dismutase: expression and effect on LDL oxidation," Gene, vol. 254, no. 1-2, pp. 173-179, 2000.
21. F. S. Ambesi-Impiombato, L. A. M. Parks, and H. G. Coon, "Culture of hormone-dependent functional epithelial cells from rat thyroids," Proceedings of the National Academy of Sciences of the United States of America, vol. 77,no. 6 I, pp. 3455-3459, 1980.
22. A. Fusco, M. T. Berlingieri, P. P. Di Fiore, G. Portella, M. Grieco, and G. Vecchio, "One-and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes," Molecular and Cellular Biology, vol. 7, no. 9, pp. 3365-3370, 1987.
23. M. Grieco, M. Santoro, M. T. Berlingieri et al., "Molecular cloning of PTC, a new oncogene found activated in human thyroid papillary carcinomas and their lymph node metastases," Annals of the New York Academy of Sciences, vol. 551, pp. 380-381, 1988.
24. M. Grieco, M. Santoro, M. T. Berlingieri et al., "PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas," Cell, vol. 60, no. 4, pp. 557-563, 1990.
25. R. Ralston and J. M. Bishop, "The protein products of the myc and myb oncogenes and adenovirus E1a are structurally related," Nature, vol. 306, no. 5945, pp. 803-806, 1983.
26. M. Tiainen, D. Spitkovsky, P. Jansen-Dürr, A. Sacchi, and M. Crescenzi, "Expression of E1A in terminally differentiated muscle cells reactivates the cell cycle and suppresses tissuespecific genes by separablemechanisms,"Molecular andCellular Biology, vol. 16, no. 10, pp. 5302-5312, 1996.
27. N. R. Lemoine, E. S. Mayall, T. Jones et al., "Characterisation of human thyroid epithelial cells immortalised in vitro by simian virus 40 DNA transfection," British Journal of Cancer, vol. 60, no. 6, pp. 897-903, 1989.
28. T. Ito, T. Seyama, T. Mizuno et al., "Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland," Cancer Research, vol. 52, no. 5, pp. 1369-1371, 1992.
29. M. Xing, "BRAFmutation in thyroid cancer," Endocrine-Related Cancer, vol. 12, no. 2, pp. 245-262, 2005.
30. L. E. Laatikainen, M. D. Castellone, A. Hebrant et al., "Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer," Endocrine-Related Cancer, vol. 17, no. 3, pp. 785-796, 2010.
31. X. Zhang, W.-L. Ng, P. Wang et al., "MicroRNA-21 modulates the levels of reactive oxygen species by targeting SOD3 and TNF," Cancer Research, vol. 72, no. 18, pp. 4707-4713, 2012.
32. T. Kamiya, H. Hara, H. Yamada, H. Imai, N. Inagaki, and T. Adachi, "Cobalt chloride decreases EC-SOD expression through intracellular ROS generation and p38-MAPK pathways in COS7 cells," Free Radical Research, vol. 42, no. 11-12, pp. 949-956, 2008.
33. M. O. Laukkanen, S. Mannermaa, M. O. Hiltunen et al., "Local hypomethylation in atherosclerosis found in rabbit ec-sod gene," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 19, no. 9, pp. 2171-2178, 1999.
34. L. E. Laatikainen,M. Incoronato, M. D. Castellone, J. P. Laurila, M. Santoro, and M. O. Laukkanen, "SOD3 decreases ischemic injury derived apoptosis through phosphorylation of Erk1/2, Akt, and Foxo3a," PLoS ONE, vol. 6, no. 8, Article ID e24456, 2011.
35. P. Str?alin and S. L. Marklund, "Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smoothmuscle cells," Atherosclerosis, vol. 151, no. 2, pp. 433-441, 2000.
36. T. Kamiya, H. Hara, N. Inagaki, and T. Adachi, "The effect of hypoxia mimetic cobalt chloride on the expression of EC-SOD in 3T3-L1 adipocytes," Redox Report, vol. 15, no. 3, pp. 131-137, 2010.
37. I. N. Zelko, M. R. Mueller, and R. J. Folz, "CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression," Free Radical Biology and Medicine, vol. 48, no. 7, pp. 895-904, 2010.
38. I. N. Zelko, M. W. Stepp, A. L. Vorst, and R. J. Folz, "Histone acetylation regulates the cell-specific and interferon-gammainducible expression of extracellular superoxide dismutase in human pulmonary arteries," American Journal of Respiratory Cell and Molecular Biology, vol. 45, no. 5, pp. 953-961, 2011.
39. F. Talotta, A. Cimmino, M. R. Matarazzo et al., "An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation," Oncogene, vol. 28,no. 1, pp. 73-84, 2009.
40. D. Frezzetti, M. De Menna, P. Zoppoli et al., "Upregulation of miR-21 by Ras in vivo and its role in tumor growth," Oncogene, vol. 30, no. 3, pp. 275-286, 2011.
41. A. J. Bardwell, E. Frankson, and L. Bardwell, "Selectivity of docking sites in MAPK kinases," The Journal of Biological Chemistry, vol. 284, no. 19, pp. 13165-13173, 2009.
42. P. Salerno, V. De Falco, A. Tamburrino et al., "Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells," Journal of Clinical Endocrinology andMetabolism, vol. 95, no. 1, pp. 450-455, 2010.
43. N. Wajapeyee, S. K. Malonia, R. K. Palakurthy, and M. R. Green, "Oncogenic RAS directs silencing of tumor suppressor genes through ordered recruitment of transcriptional repressors," Genes and Development, vol. 27, no. 20, pp. 2221-2226, 2013.
44. P. L. Jones, G. J. C. Veenstra, P. A. Wade et al., "Methylated DNA andMeCP2 recruit histone deacetylase to repress transcription," Nature Genetics, vol. 19, no. 2, pp. 187-191, 1998.
45. V. M. Richon, T. W. Sandhoff, R. A. Rifkind, and P. A. Marks, "Histone deacetylase inhibitor selectively induces p21WAF1 expressjon and gene-associated histone acetylation," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 18, pp. 10014-10019, 2000.
46. D. Wang, X. Xia, Y. Liu et al., "Negative regulation of tsh target gene by thyroid hormone involves histone acetylation and corepressor complex dissociation," Molecular Endocrinology, vol. 23, no. 5, pp. 600-609, 2009.
47. Y. Song, C. Massart, V. Chico-Galdo et al., "Species specific thyroid signal transduction: conserved physiology, divergent mechanisms," Molecular and Cellular Endocrinology, vol. 319, no. 1-2, pp. 56-62, 2010.